The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Self-reported conflicts of interest (sfCOI) of authors and the interpretation of randomized phase III trials (RCT) and related editorials (REd) in cancer research.
Giovanni Mendonca Bariani
Other Remuneration - Roche
Anezka Carvalho Rubin De Celis Ferrari
Other Remuneration - Roche
Paulo Marcelo Hoff
No relevant relationships to disclose
Rachel Riechelmann
Consultant or Advisory Role - Merck Serono; Novartis
Honoraria - Bayer; Merck Serono; Novartis; Roche
Other Remuneration - Bayer; Merck Serono; Novartis; Roche